GoAI
Get started
Vivani Medical, Inc. logo

Vivani Medical, Inc.

VANI

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.38

−$0.03 · -2.13%

Aug 21, 4:00 PM ET

VANI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

28

Expensive

Momentum

66

Gaining

Sentiment

67

Bullish

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative implantable medical devices. The firm aims to address chronic diseases for which current treatments are insufficient or lacking. Its key initiatives include a portfolio of miniature drug implants, designed to ensure consistent and stable therapeutic drug delivery, as well as advanced implantable visual prostheses intended to provide meaningful artificial vision to blind individuals. Vivani Medical is headquartered in Emeryville, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Adam Mendelsohn
Listed since
Nov 19, 2014
Employees
42

Market position

Day range

Current $1.38

52-week range

Current $1.38

Open
$1.405
Previous close
$1.41
Volume
103.38K
0.25× average
Average volume
415.19K
Average daily volume
Market cap
119M USD
Beta
3.28
Market reference 1
50-day average
$1.3156
+4.90% above average
200-day average
$1.2871
+7.22% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
79.36M USD
P/E (TTM)
-3.94×
P/B (TTM)
6.34×
P/S (TTM)
0×
EV / EBITDA
-3.03×
Earnings yield
-34.67%
Free cash flow yield
-33.22%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-169.16%
Return on assets
-67.55%
Return on invested capital
-79.68%

Financial health

Debt / equity
0.94×
Current ratio
2.71×
Altman Z-score
-4.02
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−27.56M USD-11.67%

Net income

−26.61M USD-13.30%
Income trends across reported periods−11.29M USD−17.21M USD−23.12M USD−29.03M USDOperating income, FY2021: −13.32M USDOperating income, FY2022: −21.24M USDOperating income, FY2023: −26.97M USDOperating income, FY2024: −24.68M USDOperating income, FY2025: −27.56M USDNet income, FY2021: −12.77M USDNet income, FY2022: −13.89M USDNet income, FY2023: −25.65M USDNet income, FY2024: −23.49M USDNet income, FY2025: −26.61M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −13.32M USD. Operating income FY2022 −21.24M USD. Operating income FY2023 −26.97M USD. Operating income FY2024 −24.68M USD. Operating income FY2025 −27.56M USD. Net income FY2021 −12.77M USD. Net income FY2022 −13.89M USD. Net income FY2023 −25.65M USD. Net income FY2024 −23.49M USD. Net income FY2025 −26.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold424K USD—357K USD——
Gross profit−424K USD—−357K USD——
Research and development18.13M USD15.75M USD16.97M USD14.17M USD11M USD
Selling, general, and administrative9.43M USD8.93M USD10M USD5.37M USD2.32M USD
Operating expenses27.13M USD24.68M USD26.61M USD21.24M USD13.32M USD
Depreciation and amortization424K USD400K USD357K USD381K USD345K USD
Operating income−27.56M USD−24.68M USD−26.97M USD−21.24M USD−13.32M USD
Net income−26.61M USD−23.49M USD−25.65M USD−13.89M USD−12.77M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.43
FY2025
Latest fiscal-year revenue
0 USD
FY2025

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.14-0.27-0.4-0.53FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend0.10.03-0.03-0.1FY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.00

189.86% upside
Past 12 months12-month forecastHigh $4.00Average $4.00Low $4.00

Corporate actions

Corporate action history

Stock split

Effective Aug 19, 2022

1:3

Stock split

Effective Jan 6, 2020

1:8

VANI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VANI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.42M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
824.05K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
191.01K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research VANI

research.disclaimer